Godavari Biorefineries Limited (GBL) (BSE: 544279 | NSE: GODAVARIB), a leading renewable chemicals and bio-based manufacturing group, has announced the incorporation of Sathgen Therapeutics LLC, a wholly owned step-down subsidiary headquartered in Princeton, New Jersey, USA. The move marks a significant expansion of GBL’s clinical-stage biotechnology activities, strengthening its presence in the United States with a focus on global intellectual property out-licensing and building strategic partnerships to accelerate drug development.
Sathgen Therapeutics traces its origins to a research concept proposed by Dr Sendurai Mani and supported by Samir Somaiya, Chairman and Managing Director of GBL. Over the years, this initiative has evolved into an active discovery and development program advancing multiple novel therapeutic molecules.
Several candidates have demonstrated encouraging preclinical results, particularly in triple-negative breast cancer (TNBC), along with a new class of compounds that target cancer and cancer stem cells, showing strong activity in breast and prostate cancer models. The program is protected by patents granted across the United States, Europe, China, and other major markets.
With the launch of the US subsidiary, Dr Padmaja Ganapathy has been appointed Chief Executive Officer, while Dr Sendurai Mani will serve as Chief Scientific Officer. The new entity is positioned to deepen engagement with global partners, enabling smoother progression of assets into later stages of development.
Commenting on the expansion, Mr Somaiya said the U.S. presence reinforces GBL’s long-held belief that India can contribute meaningfully to original drug discovery, particularly in challenging disease areas such as TNBC, where treatment options remain limited.
Dr Padmaja Ganapathy noted that the Princeton-based subsidiary provides a strong platform to forge collaborations that can efficiently advance and out-license Sathgen’s discoveries to benefit patients worldwide. Dr Mani added that targeting cancer stem cells remains central to the scientific strategy, with the U.S. launch enabling closer collaboration with international research and clinical partners.
Sathgen has also constituted a Scientific Advisory Board comprising global oncology experts Dr Razelle Kurzrock and Dr Massimo Cristofanilli, who will guide translational research and clinical development as the portfolio moves toward next-phase partnerships. Godavari Biorefineries Limited is among the top ethanol manufacturers in India and a frontrunner in ethanol-based chemical production. The company’s diverse portfolio includes bio-based chemicals, sugar, rectified spirits, ethanol, multiple alcohol grades, and power. GBL is uniquely positioned in the Indian market with an extensive range of bio-based products such as MPO, natural 1,3-butylene glycol, ethyl vinyl ether, and others.
